Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

Biotech investors spent years waiting for the sector to recover from its brutal 2021 peak. That patience is finally paying ...

Broadcast Retirement Network's Jeffrey Snyder discusses the state of investment in the life sciences with scientist and ...

This clinical-stage biotech focused on long-acting antibody therapies reported a notable insider sale amid ongoing pipeline ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th ...

Sulfolobus islandicus, an archaeal model organism, offers unique advantages for metabolic engineering and synthetic biology ...

The U.S. excels at funding discovery and celebrating breakthroughs, then neglects the hard work of manufacturing them at ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping ...

The companies Kymera Therapeutics, Immunovant, and Dyne Therapeutics bagged the biggest biotech funding rounds overall in ...

Merck is in talks to buy cancer drug developer Revolution Medicines in a $28 billion to $32 billion deal, the Financial Times ...